CA2662491A1 - Combinations containing a 4-acylaminopyridine derivative - Google Patents

Combinations containing a 4-acylaminopyridine derivative Download PDF

Info

Publication number
CA2662491A1
CA2662491A1 CA002662491A CA2662491A CA2662491A1 CA 2662491 A1 CA2662491 A1 CA 2662491A1 CA 002662491 A CA002662491 A CA 002662491A CA 2662491 A CA2662491 A CA 2662491A CA 2662491 A1 CA2662491 A1 CA 2662491A1
Authority
CA
Canada
Prior art keywords
cas
combination
agent
inhibitor
modulator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002662491A
Other languages
English (en)
French (fr)
Inventor
Carrolee Barlow
Todd A. Carter
Andrew Morse
Kai Treuner
Kym I. Lorrain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Braincells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braincells Inc filed Critical Braincells Inc
Publication of CA2662491A1 publication Critical patent/CA2662491A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002662491A 2006-09-08 2007-06-21 Combinations containing a 4-acylaminopyridine derivative Abandoned CA2662491A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US82508006P 2006-09-08 2006-09-08
US60/825,080 2006-09-08
US86851006P 2006-12-04 2006-12-04
US60/868,510 2006-12-04
US88458407P 2007-01-11 2007-01-11
US60/884,584 2007-01-11
PCT/US2007/071819 WO2008030651A1 (en) 2006-09-08 2007-06-21 Combinations containing a 4-acylaminopyridine derivative

Publications (1)

Publication Number Publication Date
CA2662491A1 true CA2662491A1 (en) 2008-03-13

Family

ID=38658193

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002662491A Abandoned CA2662491A1 (en) 2006-09-08 2007-06-21 Combinations containing a 4-acylaminopyridine derivative

Country Status (9)

Country Link
US (1) US7998971B2 (enExample)
EP (1) EP2068872A1 (enExample)
JP (1) JP2010502722A (enExample)
KR (1) KR20090064418A (enExample)
AU (1) AU2007292848A1 (enExample)
BR (1) BRPI0716604A2 (enExample)
CA (1) CA2662491A1 (enExample)
MX (1) MX2009002496A (enExample)
WO (1) WO2008030651A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015138A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US20090197823A1 (en) * 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2125017A2 (en) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation of neurogenesis with use of modafinil
US8426439B2 (en) * 2007-04-11 2013-04-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
WO2009145900A1 (en) * 2008-05-27 2009-12-03 Intra-Cellular Therapies, Inc. Methods and compositions for sleep disorders and other disorders
WO2010074753A1 (en) 2008-12-23 2010-07-01 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
AU2010203356B2 (en) * 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2011274787B2 (en) * 2010-07-07 2016-06-16 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8741888B2 (en) 2010-11-09 2014-06-03 Carl A. Forest Sleep aid composition and method
BR112013019265A2 (pt) * 2011-01-28 2016-10-11 Acorda Therapeutics Inc uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral
US20130064799A1 (en) * 2011-06-01 2013-03-14 Tariq M. Rana Methods for promoting cell reprogramming
SMT202000008T1 (it) 2012-01-23 2020-03-13 Sage Therapeutics Inc Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
PL2887944T3 (pl) 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
DK2968320T3 (da) 2013-03-15 2021-02-01 Intra Cellular Therapies Inc Organiske forbindelser
CA3148303C (en) 2013-12-03 2024-02-27 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carboline compounds for use in treatment of bipolar disorders
CA2944512C (en) 2014-04-04 2018-04-24 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines for treatment of central nervous system disorders
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US9402834B2 (en) 2014-10-21 2016-08-02 Ions Pharmaceutical S.À R.L. Human therapeutic agents
SI3261640T1 (sl) 2015-02-25 2022-10-28 The Regents Of The University Of California 5HT agonisti za zdravljenje epilepsijskih motenj
PT3407888T (pt) 2016-01-26 2021-03-19 Intra Cellular Therapies Inc Compostos de piridopirroloquinoxalina, suas composições e utilizações
RU2766155C2 (ru) 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
SI3407889T1 (sl) 2016-03-25 2021-09-30 Intra-Cellular Therapies, Inc. Organske spojine in njihova uporaba v zdravljenju ali preprečevanju motenj centralnega živčnega sistema
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
EP3436455A4 (en) 2016-03-28 2019-09-04 Intra-Cellular Therapies, Inc. NOVEL SALTS AND CRYSTALS
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
WO2018126143A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
KR102050537B1 (ko) * 2017-08-08 2019-12-02 서울대학교병원 포스포디에스터라아제 3 억제제를 포함하는 탈모방지 또는 발모촉진용 조성물
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
US11497723B1 (en) * 2017-12-19 2022-11-15 Tony Antakly PPAR-gamma activators, HDAC inhibitors and their therapeutical usages
US10702488B2 (en) * 2017-12-19 2020-07-07 Theriac Biomedical Inc. PPAR-γ activators, HDAC inhibitors and their therapeutical usages
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
IL277504B1 (en) 2018-03-23 2026-02-01 Intra Cellular Therapies Inc Deuterium-converted ((sa10,rb6)-8-(3-(4-fluorophenoxy)propyl 6b, 7, 8, 9, 10, 10a-hexahydro-1h-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-82(h3)-one compounds, pharmaceutical composition containing them and their uses
JP7476115B2 (ja) 2018-06-06 2024-04-30 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規の塩および結晶
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
DK3609891T3 (da) 2018-06-11 2026-02-23 Intra Cellular Therapies Inc Syntese af substituerede heterocykliske fusionerede gamma-carboliner
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
MX2021002321A (es) 2018-08-31 2021-04-28 Intra Cellular Therapies Inc Nuevos metodos.
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
EP3898221A4 (en) 2018-12-17 2022-09-14 Intra-Cellular Therapies, Inc. ORGANIC CONNECTION
WO2020132474A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compound
WO2020132605A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds
TWI727584B (zh) 2019-06-20 2021-05-11 財團法人工業技術研究院 抑制皮膚細胞增生及/或抗發炎之組成物以及芹菜素與木犀草素在製備抑制皮膚細胞增生及/或抗發炎之組成物的用途
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
JP2022549335A (ja) 2019-09-25 2022-11-24 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (576)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3121076A (en) 1964-02-11 Benzodiazepinones and processes
US1873732A (en) 1928-12-28 1932-08-23 Abbott Lab Bactericide applicable to acid-fast bacteria
US3019843A (en) 1956-07-27 1962-02-06 Powell Dawson Fire inhibitor and extinguisher
US2942572A (en) 1958-06-17 1960-06-28 Pall Corp Magnetic pressure indicator
US3371085A (en) 1959-12-10 1968-02-27 Hoffmann La Roche 5-aryl-3h-1,4-benzodiazepin-2(1h)-ones
US3136815A (en) 1959-12-10 1964-06-09 Hoffmann La Roche Amino substituted benzophenone oximes and derivatives thereof
US3116203A (en) 1962-03-14 1963-12-31 Hoffmann La Roche Oleaginous systems
NL298071A (enExample) 1963-06-04
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
NL129434C (enExample) 1966-03-12
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
BE759838A (fr) 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
FR2077918B1 (enExample) 1970-02-24 1973-04-06 Berthier Laboratoires
US3758528A (en) 1970-03-13 1973-09-11 Science Union & Cie Tricyclic compounds
US3821249A (en) 1970-03-13 1974-06-28 En Nom Collectif Science Union Dibenzothiazefin derivatives
US3819631A (en) 1970-12-15 1974-06-25 May & Baker Ltd Azapurinones
OA04285A (fr) 1972-01-07 1979-12-31 Rhone Poulenc Sa Nouveaux dérivés de la pyrrolo (3,4-b) pyrazine et leur préparation.
USRE31617E (en) 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US3932407A (en) 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
US4036840A (en) 1972-06-07 1977-07-19 Icn Pharmaceuticals 2-Substituted-s-triazolo[1,5a]pyrimidines
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4051236A (en) 1973-02-15 1977-09-27 E. R. Squibb & Sons, Inc. Inhibition of blood platelet aggregation
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4280957A (en) 1974-09-11 1981-07-28 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
AR208414A1 (es) 1974-11-07 1976-12-27 Rhone Poulenc Ind Procedimiento para obtener nuevos derivados de la((acil-4piperazinil-1)carboniloxi-5 pirrolinona-2)
US4093617A (en) 1974-11-12 1978-06-06 Icn Pharmaceuticals, Inc. 3,5,7-Trisubstituted pyrazolo[1,5-a]pyrimidines
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
NL189199C (nl) 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
FR2319338A1 (fr) 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
YU96177A (en) 1976-04-24 1982-08-31 Wuelfing Johann A Process for obtaining adenine derivatives
USRE30511E (en) 1977-02-03 1981-02-10 American Cyanamid Company Imidazo[1,5-d]-as-triazine-4(3H)-ones and thiones
US4107307A (en) 1977-02-03 1978-08-15 American Cyanamid Company Imidazo [1,5-d]-as-triazine-4(3H)-ones and thiones
CA1095906A (en) 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
US4404380A (en) 1977-02-14 1983-09-13 Mead Johnson & Company Triazolopyrimidines
US4096257A (en) 1977-05-23 1978-06-20 American Cyanamid Company Substituted imidazo [1,2-d]-as-triazines
US4107309A (en) 1977-05-23 1978-08-15 American Cyanamid Company Substituted imidazo[1,2-d]-as-triazines
IN148482B (enExample) 1977-06-03 1981-03-07 Pfizer
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
CA1086735A (en) 1977-11-03 1980-09-30 John C. Danilewicz Piperidino-quinazolines
US4370328A (en) 1977-11-03 1983-01-25 Pfizer Inc. Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4146718A (en) 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4366156A (en) 1979-03-05 1982-12-28 Mead Johnson & Company Antiallergic methods using diazaheterocyclopurines
CA1143728A (en) 1979-10-04 1983-03-29 Max Gerecke Imidazodiazepine derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS5668695A (en) 1979-11-10 1981-06-09 Sankyo Co Ltd Enzyme inhibitor griseolic acid and its preparation
US4642345A (en) 1980-08-14 1987-02-10 Mead Johnson & Company 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US4301176A (en) 1980-08-18 1981-11-17 Warner-Lambert Company Method of administering calcium valproate
US4361583A (en) 1980-08-19 1982-11-30 Synthelabo Analgesic agent
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US4489078A (en) 1980-11-24 1984-12-18 Mead Johnson & Company Diazaheterocyclopurines used as anti-broncho spasmatics and vasodilators
US4338317A (en) 1981-03-16 1982-07-06 Mead Johnson & Company Phenoxyethyl-1,2,4,-triazol-3-one antidepressants
US4383999A (en) 1981-05-26 1983-05-17 Smithkline Beckman Corporation Inhibition of GABA uptake by N-substituted azaheterocyclic carboxylic acids and their esters
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
LU83729A1 (fr) 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
CH655110A5 (de) 1982-09-03 1986-03-27 Otsuka Pharma Co Ltd Carbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten.
US4663320A (en) 1983-02-16 1987-05-05 Syntex (U.S.A.) Inc. (2-oxo-1,2,3,5-tetrahydroimidazo[2,1-b]quinoazolinyl)oxyalkylamides, compositions and the use thereof
US4490371A (en) 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
US4900836A (en) 1983-06-23 1990-02-13 American Cyanamid Company (3-amino-1H-pyrazol-4-yl) (aryl)methanones
US4626538A (en) 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4521422A (en) 1983-06-23 1985-06-04 American Cyanamid Company Aryl and heteroaryl[7-(aryl and heteroaryl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4593029A (en) 1984-02-15 1986-06-03 Syntex (U.S.A.) Inc. Novel ω-(N-imidazolyl)alkyl ethers of 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
GB8425872D0 (en) 1984-10-12 1984-11-21 Ciba Geigy Ag Chemical compounds
US4855290A (en) 1985-05-10 1989-08-08 State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research Derivatives of quinuclidine
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
ZW20586A1 (en) 1985-10-17 1988-05-25 Smith Kline French Lab Chemical compounds
US4670434A (en) 1985-11-14 1987-06-02 Syntex (U.S.A.) Inc. (2-oxo-3-methylene-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolinyl)oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
EP0261763B1 (en) 1986-06-27 1994-02-09 Beecham Group Plc Novel bridged bicyclic N-heterocycles
GB8615785D0 (en) 1986-06-27 1986-08-06 Beecham Group Plc Compounds
FR2600650B1 (fr) 1986-06-27 1988-09-09 Synthelabo Procede de preparation d'imidazopyridines et composes intermediaires
US4701459A (en) 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4709094A (en) 1986-07-10 1987-11-24 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Sigma brain receptor ligands and their use
US5312840A (en) 1986-07-10 1994-05-17 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education Substituted guanidines having high binding to the sigma receptor and the use thereof
US5385946A (en) 1986-07-10 1995-01-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Method for treating hypertension with disubstituted granidine compounds
US5093525A (en) 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4761416A (en) 1986-07-25 1988-08-02 Syntex (U.S.A.) Inc. N-N-disubstituted-ω-[2-amino-3-(carbonylmethyl)-3, 4-dihydroquinazolinyl]oxyalkylamides and related compounds
US4739056A (en) 1986-11-26 1988-04-19 Syntex (U.S.A.) Inc. N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl)oxy-alkylamides and related compounds
US4710508A (en) 1986-12-08 1987-12-01 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4786648A (en) 1986-12-08 1988-11-22 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
US4766118A (en) 1986-12-22 1988-08-23 Ortho Pharmaceutical Corporation 6-benzoxazinyl- and 6-benzothiazinyl-2,3,4,5-tetrahydropyridazin-3-ones and pharmaceutical use
US5081242A (en) 1986-12-22 1992-01-14 Ortho Pharmaceutical Corporation 6-benzoxazinyl- and 6-benzothiazinyl 2,3,4,5-tetrahydropyridazin-3-ones
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US4721784A (en) 1986-12-22 1988-01-26 Ortho Pharmaceutical Corporation 6-benzoxazinyl-2,3,4,5-tetrahydropyridazin-3-ones
US4992457A (en) 1987-03-18 1991-02-12 Schulman Jerome M Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease
US4929734A (en) 1987-03-31 1990-05-29 Warner-Lambert Company Tetrahydropyridine oxime compounds
EP0287356B1 (en) 1987-04-15 1996-01-24 Beecham Group Plc Bridgehead substituted azabicyclic derivatives
GB8714789D0 (en) 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US4981858A (en) 1987-08-13 1991-01-01 State Of Israel, Represented By The Prime Minister's Office, Israel Institute For Biological Research Optical isomers
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
USRE35517E (en) 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
ATE122353T1 (de) 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
US5412096A (en) 1987-10-05 1995-05-02 Yamanouchi Pharmaceutical Co., Ltd. Hydrochloride salts of heterocyclic spiro compounds
IE63906B1 (en) 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
EP0322182A3 (en) 1987-12-22 1992-01-02 Beecham Group Plc Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5091431A (en) 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
PT90266B (pt) 1988-04-15 1994-07-29 Beecham Group Plc Processo para a preparacao de compostos azabiciclicos
US4957916A (en) 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US4861891A (en) 1988-08-31 1989-08-29 Pfizer Inc. Antidepressant N-substituted nicotinamide compounds
CA2000041A1 (en) 1988-10-13 1990-04-13 Barry S. Orlek Compounds
DE8817121U1 (de) 1988-11-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Quinuclidine
US5286864A (en) 1988-11-22 1994-02-15 Boehringer Ingelheim Kg Quinuclidines, their use as medicaments and processes for their preparation
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4971972A (en) 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
SG48315A1 (en) 1989-04-13 1998-04-17 Beecham Group Plc Novel compounds
US5278170A (en) 1989-04-13 1994-01-11 Beecham Group P.L.C. Azabicylo oxime compounds
US4956368A (en) 1989-07-24 1990-09-11 Bristol-Myers Company Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
US5109002A (en) 1989-09-08 1992-04-28 Du Pont Merck Pharmaceutical Company Antipsychotic 1-cycloalkylpiperidines
EP0427390B1 (en) 1989-10-07 1996-03-27 Beecham Group Plc Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them
US4943573A (en) 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
CA2029497C (en) 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative
US5010086A (en) 1990-02-28 1991-04-23 Sterling Drug Inc. Imidazopyridines, compositions and use
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
US5149817A (en) 1990-03-05 1992-09-22 Shionogi & Co., Ltd. Teirahydropyridine derivatives
GB9005737D0 (en) 1990-03-14 1990-05-09 Beecham Group Plc Novel compounds
US5169855A (en) 1990-03-28 1992-12-08 Du Pont Merck Pharmaceutical Company Piperidine ether derivatives as psychotropic drugs or plant fungicides
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5407938A (en) 1990-04-10 1995-04-18 Israel Institute For Biological Research Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
US5116995A (en) 1990-05-25 1992-05-26 Taisho Pharmaceutical Co., Ltd. Carbazole compounds
WO1991018868A1 (en) 1990-05-25 1991-12-12 STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION, acting for and onbehalf of the OREGON HEALTH SCIENCES UNIVERSITY Substituted guanidines having high binding to the sigma receptor and the use thereof
US5612211A (en) 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5095015A (en) 1990-07-24 1992-03-10 Neurogen Corporation Certain azacycloalkyl imidazopyrimidines; a new class of gaba brain receptor ligands
JP2935541B2 (ja) 1990-06-28 1999-08-16 サントリー株式会社 縮合複素環化合物
US5086054A (en) 1990-07-31 1992-02-04 Sri International Novel arylcycloalkanepolyalkylamines
US5376668A (en) 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
DK198590D0 (da) 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5527813A (en) 1990-08-21 1996-06-18 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
WO1992003435A1 (en) 1990-08-24 1992-03-05 Beecham Group Plc Azabicyclic compounds, process and intermediates for their preparation and pharmaceutical compositions containing them
CA2050264A1 (en) 1990-08-30 1992-03-01 Raymond Baker Substituted pyrazine and its salts, compositions containing them and their use in medicine
GB9019095D0 (en) 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds
US5185446A (en) 1990-09-04 1993-02-09 Neurogen Corporation Certain cycloalkyl imidazopyrimidines; a new class of gaba brainreceptor ligands
JPH06502147A (ja) 1990-10-09 1994-03-10 ニューロゲン　コーポレイション 或る種のシクロアルキルおよびアザシクロアルキルピロロピリミジン；新規な種類のｇａｂａ脳リセプタリガンド
CA2093823A1 (en) 1990-10-12 1992-04-13 Steven M. Bromidge 1,2,5,6-tetrahydropyridine oxime derivatives
US5139802A (en) 1990-10-15 1992-08-18 Nestec S.A. Oxidation of tea
ATE118306T1 (de) 1990-10-15 1995-03-15 Nestle Sa Behandlung von schwarzem tee.
US5091242A (en) 1990-10-30 1992-02-25 The Research Foundation Of State Univ. Of N.Y. Carbon fiber composites having improved fatigue resistance
US6268496B1 (en) 1990-10-31 2001-07-31 Neurogen Corporation Certain imidazoquinoxalines: a new class of GABA brain receptor ligands
US5130430A (en) 1990-10-31 1992-07-14 Neurogen Corporation 2-substituted imidazoquinoxaline diones, a new class of gaba brain receptor ligands
US5744602A (en) 1990-10-31 1998-04-28 Neurogen Corporation Certain imidazoquinoxalines; a new class of GABA brain receptor ligands
US5116837A (en) 1990-12-21 1992-05-26 Ortho Pharmaceutical Corporation 2,9-dihydro-(6 or 7)-(3-oxo-2,3,4,5-tetrahydropyridazinyl)-pyrazolo [4,3-B]-1,4-benzoxazines
US5162341A (en) 1991-02-22 1992-11-10 Du Pont Merck Pharmaceutical Company Use of sigma receptor antagonists for treatment of amphetamine abuse
US5137895A (en) 1991-04-29 1992-08-11 A. H. Robins Company, Incorporated 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols
US5093333A (en) 1991-04-29 1992-03-03 American Home Products Corporation N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system
US5124460A (en) 1991-05-06 1992-06-23 Merck Sharp & Dohme Ltd. Enantioselective synthesis of 3-substituted 1-azabicyclo (2.2.1)heptanes
DE69226187T2 (de) 1991-05-15 1998-10-22 Yamanouchi Pharma Co Ltd (-)-(s)-2,8-dimethyl-3-methylen-1-oxa-8-azaspiro(4,5)decan l-tartrat
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
US5641791A (en) 1991-08-13 1997-06-24 Novo Nordisk A.S Heterocyclic compounds and their preparation and use
US5182386A (en) 1991-08-27 1993-01-26 Neurogen Corporation Certain imidazoquinoxalinones; a new class of gaba brain receptor ligands
US5182290A (en) 1991-08-27 1993-01-26 Neurogen Corporation Certain oxazoloquinolinones; a new class of GABA brain receptor ligands
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5585490A (en) 1991-10-08 1996-12-17 Neurogen Corporation Certain cycloalkyl and azacycloalkyl pyrrolopyrimidines; a new class of GABA brain receptor ligands
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5243049A (en) 1992-01-22 1993-09-07 Neurogen Corporation Certain pyrroloquinolinones: a new class of GABA brain receptor ligands
MX9300875A (es) 1992-02-20 1993-08-31 Smithkline Beecham Plc Procedimiento para la preparacion de compuestos azabiciclicos.
US6225115B1 (en) 1992-03-04 2001-05-01 Synaptic Pharmaceutical Corporation DNA encoding taurine and GABA transporters and uses thereof
US5298657A (en) 1992-03-20 1994-03-29 Cambridge Neuroscience Inc. Preparation of substituted guanidines
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5367077A (en) 1992-04-08 1994-11-22 Neurogen Corporation Certain cycloalkyl and azacycloalkyl pyrrolopyridines; a new class of gaba rain receptor ligands
WO1994025463A1 (en) 1992-04-08 1994-11-10 Neurogen Corporation Certain aryl fused pyrrolopyrimidines; a new class of gaba brain receptor ligands
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
SE9201478D0 (sv) 1992-05-11 1992-05-11 Kabi Pharmacia Ab Heteroaromatic quinuclidinenes, their use and preparation
ES2060547B1 (es) 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
GB9212673D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9212693D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
JP2683783B2 (ja) 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤
US5672499A (en) 1992-07-27 1997-09-30 California Institute Of Technology Immoralized neural crest stem cells and methods of making
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
ZA937382B (en) 1992-10-06 1994-04-29 Warner Lambert Co Novel composition for peroral therapy of cognitionimpairment and a process therefor
GB9222253D0 (en) 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5668283A (en) 1992-11-12 1997-09-16 Neurogen Corporation Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands
US5286860A (en) 1992-11-12 1994-02-15 Neurogen Corporation Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US5622977A (en) 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
AU5991294A (en) 1993-01-06 1994-08-15 Neurogen Corporation Certain aryl substituted imidazopyrazinones a new class of gaba brain receptor ligands
ES2098799T3 (es) 1993-01-23 1997-05-01 Hoechst Ag 2,3-difluoro-6-nitro-benzonitrilo y 2-cloro-5,6-difluoro-benzonitrilo, procedimiento para su preparacion y su utilizacion para la preparacion de acido 2,3,6-trifluoro-benzoico.
US5424301A (en) 1993-02-01 1995-06-13 Warner-Lambert Company Starch stabilized o-substituted tetrahydropyridine oxime cholinergic agents
US5362860A (en) 1993-02-01 1994-11-08 Warner-Lambert Company Neutral stabilization complex for CI-979 HCl, a cognition activator
US6013799A (en) 1993-03-03 2000-01-11 Neurogen Corporation Certain cycloalkyl imidazopyrimides, a new class of gaba brain receptor ligands
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
WO1994022843A1 (en) 1993-03-26 1994-10-13 Schering Corporation 2-substituted morpholine and thiomorpholine derivatives as gaba-b antagonists
US5750702A (en) 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
ES2204920T3 (es) 1993-05-27 2004-05-01 Cenes Limited Guanidinas substituidas terapeuticas.
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6087346A (en) 1993-06-23 2000-07-11 Cambridge Neuroscience, Inc. Sigma receptor ligands and the use thereof
DE59410119D1 (de) 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
ES2074946B1 (es) 1993-07-19 1996-06-16 Ferrer Int Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
US5665754A (en) 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5484944A (en) 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
EP0730587B1 (en) 1993-11-26 1999-12-08 Pfizer Inc. 3-phenyl-2-isoxazolines as antiinflammatory agents
ATE154932T1 (de) 1993-11-26 1997-07-15 Pfizer Isoxazolinverbindungen als entzündungshemmende mittel
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US5500420A (en) 1993-12-20 1996-03-19 Cornell Research Foundation, Inc. Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
GB9326173D0 (en) 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
ATE260911T1 (de) 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326699D0 (en) 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
EP0734723A4 (en) 1993-12-29 2001-04-11 Kowa Tekuno Sachi Co Ltd THERAPEUTIC COMPOSITION USEFUL FOR TREATING HYPERPARATHYROIDIA OF A PATIENT ON ARTIFICIAL DIALYSIS
US7060450B1 (en) 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
DK0752860T3 (da) 1994-02-14 2000-11-13 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5783575A (en) 1994-03-14 1998-07-21 Novo Nordisk A/S Antagonists, their preparation and use
US5696148A (en) 1994-03-14 1997-12-09 Novo Nordisk A/S Indole compounds and their use in treating diseases of the central nervous system
AU697183B2 (en) 1994-03-14 1998-10-01 Novo Nordisk A/S Thieno{ 2,3-b}indoles, their preparation and use
US5637617A (en) 1994-04-01 1997-06-10 The Regents Of The University Of California Methods for use of GABAa receptor GABAergic compounds
GB9409718D0 (en) 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
GB9409705D0 (en) 1994-05-14 1994-07-06 Smithkline Beecham Plc Novel compounds
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
JP2852608B2 (ja) 1994-06-27 1999-02-03 雪印乳業株式会社 口腔乾燥症治療剤
US5661184A (en) 1994-08-12 1997-08-26 Eli Lilly And Company Psychiatric agents
PT777671E (pt) 1994-08-24 2000-08-31 Astrazeneca Ab Compostos espiro-azabiciclicos uteis em terapia
US5817670A (en) 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof
US5731307A (en) 1994-09-30 1998-03-24 Pfizer, Inc. Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines
US5554645A (en) 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
DE4436509A1 (de) 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
JP3993651B2 (ja) 1994-10-21 2007-10-17 アスビオファーマ株式会社 シクロプロパクロメンカルボン酸誘導体
US5821370A (en) 1994-10-24 1998-10-13 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5605908A (en) 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5473077A (en) 1994-11-14 1995-12-05 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor agonists
US5571819A (en) 1994-11-22 1996-11-05 Sabb; Annmarie L. Imidazopyridines as muscarinic agents
US5510478A (en) 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5512574A (en) 1994-12-21 1996-04-30 American Home Products Corporation Quinuclidine and azabicyclo 2.2.1! heptane pyrazinyl ethers as muscarinic agonists
US5468875A (en) 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives
GB9503601D0 (en) 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
US5488055A (en) 1995-03-10 1996-01-30 Sanofi Winthrop Inc. Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
RU2135493C1 (ru) 1995-04-21 1999-08-27 Нюросерч А/С Производное бензимидазола, фармацевтический состав и способ модуляции гамка-рецепторного комплекса
AU5644396A (en) 1995-05-05 1996-11-21 Novo Nordisk A/S Novel heterocyclic chemistry
DE19518082A1 (de) 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
DE59610031D1 (de) 1995-05-18 2003-02-06 Altana Pharma Ag Cyclohexyldihydrobenzofurane
AU698028B2 (en) 1995-05-18 1998-10-22 Altana Pharma Ag Phenyldihydrobenzofurans
US6514996B2 (en) 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
US5637725A (en) 1995-06-05 1997-06-10 Neurogen Corporation Substituted aryl and cycloalkyl imidazolones; a new class of GABA brain receptor ligands
US5637724A (en) 1995-06-05 1997-06-10 Neurogen Corporation Substituted aryl and cycloalkyl imidazolones; a new class of GABA brain receptor ligands
EP1288220A3 (en) 1995-06-06 2004-07-21 Euro-Celtique Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series
US5910590A (en) 1995-06-07 1999-06-08 Neurogen Corporation Certain aryl substituted pyrrolopyrazines; a new class of GABA brain receptor ligands
US5534522A (en) 1995-06-07 1996-07-09 Warner-Lambert Company (R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
WO1997005105A1 (en) 1995-07-26 1997-02-13 Pfizer Inc. N-(aroyl)glycine hydroxamic acid derivatives and related compounds
US20010018074A1 (en) 1995-07-29 2001-08-30 Smithkline Beecham P.L.C. Process for preparing solid dosage forms of very low-dose drugs
US5945417A (en) 1995-07-31 1999-08-31 Novo Nordisk Heterocyclic compounds, their preparation and use
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US5800539A (en) 1995-11-08 1998-09-01 Emory University Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease
US5912248A (en) 1995-11-16 1999-06-15 Eli Lilly And Company Excitatory amino acid receptor antagonists
ZA969485B (en) 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
US5756501A (en) 1995-12-13 1998-05-26 American Home Products Corporation Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents
GB9603723D0 (en) 1996-02-22 1996-04-24 Merck & Co Inc Diphenyl pyridyl derivatives as pde iv inhibitors
US5710170A (en) 1995-12-15 1998-01-20 Merck Frosst Canada, Inc. Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
US5804686A (en) 1996-01-19 1998-09-08 Neurogen Corporation fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
US6211365B1 (en) 1996-01-19 2001-04-03 Neurogen Corporation Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands
BR9707233A (pt) 1996-01-31 1999-07-20 Byk Gulden Lomberg Chem Fab Fenantridinas
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
US5792766A (en) 1996-03-13 1998-08-11 Neurogen Corporation Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands
US5677309A (en) 1996-03-22 1997-10-14 Neurogen Corporation 1,2,4-triazolo 4,3-c! quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones; a new class of GABA brain receptor ligands
AU2218997A (en) 1996-03-22 1997-10-10 Neurogen Corporation Certain fused pyrrolecarboxamides as gaba brain receptor ligands
US6127378A (en) 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
FR2746800B1 (fr) 1996-03-29 1998-06-05 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases 4
US6297273B1 (en) 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
FR2754260B1 (fr) 1996-10-04 1998-10-30 Adir Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5723462A (en) 1996-04-26 1998-03-03 Neurogen Corporation Certain fused pyrrolecarboxamides a new class of GABA brain receptor ligands
US20020103194A1 (en) 1997-04-30 2002-08-01 Anabella Villalobos Novel muscarinic receptor agonists
PL329875A1 (en) 1996-05-10 1999-04-12 Icos Corp Derivatives of carbolin
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US20020127271A1 (en) 1996-07-25 2002-09-12 Smithkline Beecham P.L.C. Formulation for the treatment and/or prophylaxis of dementia
AU723098B2 (en) 1996-07-25 2000-08-17 Merck Sharp & Dohme Limited Substituted triazolo-pyridazine derivatives as ligands for GABA receptors
NZ334613A (en) 1996-08-12 2002-02-01 Welfide Corp Pharmaceutical agents comprising Rho kinase inhibitor
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
ATE229516T1 (de) 1996-08-19 2002-12-15 Altana Pharma Ag Benzofuran-4-carboxamide
SI0920426T1 (en) 1996-08-26 2004-04-30 Altana Pharma Ag New thiazole derivatives with phosphodiesterase-inhibiting effect
US20010003588A1 (en) 1996-09-12 2001-06-14 Smithkline Beecham Corporation Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
US5834458A (en) 1996-10-09 1998-11-10 Eli Lilly And Company Heterocyclic compounds and their use
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
GB9621789D0 (en) 1996-10-18 1996-12-11 Lilly Industries Ltd Pharmaceutical compounds
NZ334868A (en) 1996-10-21 2001-02-23 Neurosearch As 1-Phenyl-benzimidazole compounds and their use as BAGA-a receptor modulators
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US5773458A (en) 1996-10-30 1998-06-30 American Home Products Corporation 1-azabicycloheptane derivatives
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6069151A (en) 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
JP2001504462A (ja) 1996-11-12 2001-04-03 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング ホスホジエステラーゼ阻害剤としての（２，３―ジヒドロベンゾフラニル）―チアゾール
SI0941221T1 (en) 1996-11-20 2003-10-31 Altana Pharma Ag Substituted dihydrobenzofurans as pde inhibitors
GB9625184D0 (en) 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
ES2193508T3 (es) 1997-01-15 2003-11-01 Altana Pharma Ag Ftalizinonas.
GB9702524D0 (en) 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
DK0975347T3 (da) 1997-02-28 2008-06-16 Nycomed Gmbh Synergistisk kombination af PDE-inhibitorer og adenylatcyclase-agonister eller guanylcyclyseagonister
ES2131463B1 (es) 1997-04-08 2000-03-01 Lilly Sa Derivados de ciclopropilglicina con propiedades farmaceuticas.
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
GB9708945D0 (en) 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
ES2179490T3 (es) 1997-05-08 2003-01-16 Merck Sharp & Dohme Derivados de 1,2,4-triazolo(3,4-a)ftalazina sustituidos como ligandos de gaba alfa 5.
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
WO1998053820A1 (en) 1997-05-29 1998-12-03 H. Lundbeck A/S Treatment of schizophrenia and psychosis
WO1999003822A1 (en) 1997-07-18 1999-01-28 Georgetown University Bicyclic metabotropic glutamate receptor ligands
US6825211B1 (en) 1997-07-18 2004-11-30 Georgetown University Bicyclic metabotropic glutamate receptor ligands
ES2189235T3 (es) 1997-07-25 2003-07-01 Altana Pharma Ag 6-fenilfenantridinas sustituidas.
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
GB9715977D0 (en) 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
US6107295A (en) 1997-08-01 2000-08-22 Merck Patent Gesellschaft Mit Beschrankter Haftung Arylalkanoyl pyridazines
CA2268190A1 (en) 1997-08-06 1999-02-18 Suntory Limited 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor
US6143760A (en) 1997-08-25 2000-11-07 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
US6207842B1 (en) 1997-10-09 2001-03-27 Mars Incorporated Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives
US6156753A (en) 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
UA64769C2 (uk) 1997-11-07 2004-03-15 Х. Луннбек А/С Гідрогалогеніди 1'-[4-[1-(4-фторофеніл)-1н-індол-3-іл]-1-бутил]-спіро[ізобензофуран-1(3н),4'-піперидину], фармацевтична композиція та спосіб лікування
TR200001338T2 (tr) 1997-11-12 2000-08-21 Bayer Aktiengesellschaft 2-Fenil-ikameli imidazotriazinonlar
US6429207B1 (en) 1997-11-21 2002-08-06 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
US6040447A (en) 1997-12-12 2000-03-21 Euro-Celtique S.A. Purine compounds having PDE IV inhibitory activity and methods of synthesis
IT1296985B1 (it) 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
EP1047697A1 (en) 1998-01-14 2000-11-02 MERCK SHARP & DOHME LTD. Triazolo-pyridazine derivatives as ligands for gaba receptors
GB9801234D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
AU748737B2 (en) 1998-01-21 2002-06-13 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for GABA receptors
GB9801202D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801210D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801208D0 (en) 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
GB9801397D0 (en) 1998-01-22 1998-03-18 Merck Sharp & Dohme Therapeutic agents
KR20010005830A (ko) 1998-01-29 2001-01-15 도리이 신이치로 타입 ⅳ 포스포디에스테라제 억제활성을 지닌 1-사이클로알킬-1,8-나프틸리딘-4-온 유도체
US6166203A (en) 1998-02-26 2000-12-26 Neurogen Corporation Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands
AU2881199A (en) 1998-02-26 1999-09-15 Neurogen Corporation Substituted 1,4-dihydro-4-oxonicotinic carboxamides: gaba brain receptor ligands
WO1999043681A1 (en) 1998-02-26 1999-09-02 Neurogen Corporation 4-(4-piperidylmethylamino) substituted heteroaryl fused pyridines: gaba brain receptor ligands
CA2322167A1 (en) 1998-02-26 1999-09-02 Neurogen Corporation Substituted cycloalkyl-4-oxonicotinic carboxamides; gaba brain receptor ligands
US6900228B1 (en) 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
US6805883B2 (en) 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
GB9806102D0 (en) 1998-03-20 1998-05-20 Merck Sharp & Dohme Therapeutic agents
FR2776660B1 (fr) 1998-03-27 2000-05-12 Parke Davis Diazepino-indoles de phosphodiesterases iv
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
JP2002512214A (ja) 1998-04-17 2002-04-23 ケネス カリー， 代謝生成物産生グルタミン酸レセプターアンタゴニストとしてのキュバン誘導体およびそれらの調製プロセス
EP1371647B1 (en) 1998-04-20 2005-07-13 Pfizer Inc. Pyridine-3-carboxylic acid derivatives and their use as intermediates
DE59913617D1 (de) 1998-04-28 2006-08-03 Elbion Ag Indolderivate und deren Verwendung als Inhibitoren der Phosphodiesterase 4.
US6897305B2 (en) 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6303789B1 (en) 1998-06-10 2001-10-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors
GB9813006D0 (en) 1998-06-16 1998-08-12 Merck Sharp & Dohme Therapeutic agents
JP2002518391A (ja) 1998-06-16 2002-06-25 メルク シャープ エンド ドーム リミテッド Ｇａｂａ受容体のリガンドとしてのトリアゾロ−ピリジン誘導体
US6417185B1 (en) 1998-06-19 2002-07-09 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CA2336894A1 (en) 1998-07-06 2000-01-13 Byk Gulden Lomberg Chemische Fabrik Gmbh New benzoxazoles with pde-inhibiting activity
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
US6177569B1 (en) 1998-08-25 2001-01-23 Neurogen Corporation Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
DK1110943T3 (da) 1998-08-31 2004-10-11 Taisho Pharmaceutical Co Ltd 6-fluorbicyclo[3.1.0]hexanderivater
CH694053A5 (de) 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
KR20010073099A (ko) 1998-09-03 2001-07-31 히라타 다다시 함산소 복소환 화합물
CA2339630C (en) 1998-09-16 2006-05-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
US6719520B2 (en) 1998-10-08 2004-04-13 Smithkline Beecham Corporation Method and compounds
AU760688B2 (en) 1998-10-16 2003-05-22 Merck Sharp & Dohme Limited Pyrazolo-triazine derivatives as ligands for GABA receptors
WO2000027849A2 (en) 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
PE20001236A1 (es) 1998-11-13 2000-11-10 Lilly Co Eli Moduladores del receptor de aminoacidos excitadores
SE9804064D0 (sv) 1998-11-25 1998-11-25 A & Science Invest Ab Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
US6130333A (en) 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
WO2000037471A1 (en) 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
EP1149102B1 (en) 1999-01-27 2004-12-08 MERCK SHARP & DOHME LTD. Triazolo-pyridazine derivatives as ligands for gaba receptors
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6498176B1 (en) 1999-03-04 2002-12-24 Smithklinebeecham Corporation 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
US6479470B1 (en) 1999-04-28 2002-11-12 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
FR2792938B1 (fr) 1999-04-28 2001-07-06 Warner Lambert Co NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6316472B1 (en) 1999-05-13 2001-11-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6448246B1 (en) 1999-05-25 2002-09-10 Neurogen Corporation Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands
WO2000075101A1 (en) 1999-06-03 2000-12-14 Lilly, S.A. Excitatory amino acid receptor modulators
WO2000077045A1 (fr) 1999-06-10 2000-12-21 Takeda Chemical Industries, Ltd. Proteine et adn de cette proteine
US6146876A (en) 1999-06-11 2000-11-14 Millennium Pharmaceuticals, Inc. 22025, a novel human cyclic nucleotide phosphodiesterase
US6297256B1 (en) 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
DE19928146A1 (de) 1999-06-19 2000-12-21 Merck Patent Gmbh Thienopyrimidine
CZ2002233A3 (cs) 1999-07-21 2002-04-17 Fujisawa Pharmaceutical Co., Ltd. Benzimidazolonové deriváty, způsob jejich výroby a farmaceutický prostředek
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
DE60006618T2 (de) 1999-08-06 2004-09-23 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
US6476019B1 (en) 1999-08-13 2002-11-05 Sepracor Inc. Spirocyclic ligands for sigma receptors, and libraries and methods of use thereof
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
GB9919957D0 (en) 1999-08-23 1999-10-27 Merck Sharp & Dohme Therapeutic agents
US20050014939A1 (en) 1999-08-31 2005-01-20 Neurogen Corporation Fused pyrrolecarboxamides: GABA brain receptor ligands
US6956049B1 (en) 1999-08-31 2005-10-18 Merck & Co., Inc. Methods of modulating processes mediated by excitatory amino acid receptors
GB9921150D0 (en) 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
GB9921351D0 (en) 1999-09-09 1999-11-10 Merck Sharp & Dohme Therapeutic agents
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
MXPA02003740A (es) 1999-10-15 2002-09-30 Hoffmann La Roche Derivados de benzodiazepina.
US7491742B2 (en) 1999-10-21 2009-02-17 Merck Patent Gmbh Imidazole derivatives as phosphodiesterase VII inhibitors
US6534287B1 (en) 1999-10-25 2003-03-18 Nps Pharmaceuticals, Inc. Human metabotropic glutamate receptor
AR029185A1 (es) 1999-10-25 2003-06-18 Yamanouchi Pharma Co Ltd Derivado de naftiridina
DE19953025A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Pyrrolderivate als Phosphodiesterase VII-Hemmer
DE19953414A1 (de) 1999-11-06 2001-05-10 Merck Patent Gmbh Imidazopyridinderivate als Phospodiesterase VII-Hemmer
DE19954707A1 (de) 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
GB9927687D0 (en) 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
JP4825387B2 (ja) 1999-12-08 2011-11-30 あすか製薬株式会社 新規な１，８−ナフチリジン−２（１ｈ）−オン誘導体
ES2213996T3 (es) 1999-12-08 2004-09-01 Centre National De La Recherche Scientifique (Cnrs) Uso de himenialdisina o sus derivados en la fabricacion de medicamentos.
GB9929687D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
US6376489B1 (en) 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6680336B2 (en) 1999-12-15 2004-01-20 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
CN100335479C (zh) 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6313156B1 (en) 1999-12-23 2001-11-06 Icos Corporation Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
US6569885B1 (en) 1999-12-23 2003-05-27 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6294561B1 (en) 1999-12-23 2001-09-25 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6372777B1 (en) 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6348602B1 (en) 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0000564D0 (en) 2000-01-11 2000-03-01 Merck Sharp & Dohme Therapeutic agents
AU2700301A (en) 2000-01-31 2001-08-14 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
JP2003523741A (ja) 2000-02-01 2003-08-12 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｂｃｌ−２様ポリヌクレオチド、ポリペプチドおよび抗体
US6800651B2 (en) 2000-02-03 2004-10-05 Eli Lilly And Company Potentiators of glutamate receptors
US20010039275A1 (en) 2000-02-04 2001-11-08 Bowler Andrew Neil Use of 2,4-diaminothiazole derivatives
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
GB0003254D0 (en) 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
FR2804959B1 (fr) 2000-02-15 2006-04-28 Centre Nat Rech Scient Utilisation de derives de paullones pour la fabrication de medicaments
IL151533A0 (en) 2000-02-29 2003-04-10 Mitsubishi Pharma Corp Novel cyclic amide derivatives
GB0005700D0 (en) 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
AU2001250892A1 (en) 2000-03-20 2001-10-03 Teva Pharmaceutical Industries Ltd. Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and n-(4-methoxyphenyl)-3-chloropropionamide
DE60125026T2 (de) 2000-03-23 2007-06-28 Takeda Pharmaceutical Co. Ltd. Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
AU2001248701A1 (en) 2000-03-24 2001-10-03 Methylgene, Inc. Inhibitors of histone deacetylase
GB0007193D0 (en) 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
GB0008696D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic agents
PL357822A1 (pl) 2000-04-14 2004-07-26 Mars Incorporated Kompozycje i sposoby polepszania stanu zdrowia układu naczyniowego
CA2306170A1 (en) 2000-04-18 2001-10-18 Kenneth Curry Novel amino, carboxy derivatives of barbituric acid
RU2269523C2 (ru) 2000-04-28 2006-02-10 Акадиа Фармасьютикалз, Инк. Мускариновые агонисты
CA2408747C (en) 2000-05-11 2011-04-05 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
US20040077599A1 (en) 2000-05-11 2004-04-22 Kenneth Curry Novel spiro[2.4]heptane amino carboxy compounds and derivatives thereof
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
EP1294723A1 (en) 2000-05-24 2003-03-26 MERCK SHARP & DOHME LTD. 3-phenyl-imidazo-pyrimidine derivatives as ligands for gaba receptors
EP1289383B1 (fr) 2000-05-30 2006-05-03 Societe Des Produits Nestle S.A. Composition primaire contenant un compose bioactif lipophile
US7081481B2 (en) 2000-05-31 2006-07-25 Eli Lilly And Company Excitatory amino acid receptor modulators
AU2001281802A1 (en) 2000-06-07 2001-12-17 Almirall Prodesfarma, S.A. 6-phenylpyrrolopyrimidinedione derivatives
CA2412596C (en) 2000-06-23 2007-07-31 Lilly Icos Llc Cyclic gmp-specific phosphodiesterase inhibitors
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6399641B1 (en) 2000-07-13 2002-06-04 Hoffmann-La Roche Inc. 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
WO2002009713A2 (de) 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
IL154425A0 (en) 2000-08-24 2003-09-17 Univ Tennessee Res H Corp Selective androgen receptor modulators and methods of use thereof
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
WO2002022579A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2266258T3 (es) 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4975941B2 (ja) 2000-09-29 2012-07-11 トポターゲット ユーケー リミテッド （ｅ）−ｎ−ヒドロキシ−３−（３−スルファモイル−フェニル）アクリルアミド化合物及びその治療用途
WO2002026696A1 (en) 2000-09-29 2002-04-04 Prolifix Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
EP1193261A1 (en) 2000-10-02 2002-04-03 Warner-Lambert Company New thiadiazoles and their use as phosphodiesterase-7 inhibitors
IL155163A0 (en) 2000-10-02 2003-10-31 Janssen Pharmaceutica Nv Metabotropic glutamate receptor antagonists
US20020103192A1 (en) 2000-10-26 2002-08-01 Curtin Michael L. Inhibitors of histone deacetylase
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
ATE310740T1 (de) 2000-11-10 2005-12-15 Merck Sharp & Dohme Imidazotriazin-derivate als liganden für gaba- rezeptoren
GB0027561D0 (en) 2000-11-10 2000-12-27 Merck Sharp & Dohme Therapeutic agents
AU2002229541B2 (en) 2000-11-14 2007-01-18 Altana Pharma Ag (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
AR035659A1 (es) 2000-12-07 2004-06-23 Hoffmann La Roche Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
JP2004517843A (ja) 2000-12-13 2004-06-17 バイエル アクチェンゲゼルシャフト ピロロ［２．１−ａ］ジヒドロイソキノリンおよびホスホジエステラーゼ１０ａ阻害薬としてのその使用
US6900215B2 (en) 2000-12-15 2005-05-31 Merck Sharp & Dohme Ltd. Imidazo-pyrimidine derivatives as ligands for gaba receptors
US6562995B1 (en) 2000-12-21 2003-05-13 Beacon Laboratories, Inc. Delta dicarbonyl compounds and methods for using the same
EP1345925B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6720445B2 (en) 2000-12-21 2004-04-13 Beacon Laboratories, Inc. Acetyloxymethyl esters and methods for using the same
CA2432077C (en) 2000-12-22 2011-01-18 F. Hoffmann-La Roche Ag Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
AR035513A1 (es) 2000-12-23 2004-06-02 Hoffmann La Roche Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
AR035417A1 (es) 2001-01-27 2004-05-26 Hoffmann La Roche Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
KR20030070150A (ko) 2001-01-31 2003-08-27 화이자 프로덕츠 인크. Ｐｄｅ4 이소자임 억제제로서 유용한 에테르 유도체
JP2004520386A (ja) 2001-01-31 2004-07-08 ファイザー・プロダクツ・インク Ｐｄｅ４アイソザイムの阻害剤として有用なニコチンアミドビアリール誘導体
OA12542A (en) 2001-01-31 2006-06-05 Pfizer Prod Inc Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes.
US6559159B2 (en) 2001-02-01 2003-05-06 Research Triangle Institute Kappa opioid receptor ligands
US6617357B2 (en) 2001-03-06 2003-09-09 Smithkline Beecham Corporation Compounds and their use as PDE inhibitors
US20020177594A1 (en) 2001-03-14 2002-11-28 Curtin Michael L. Inhibitors of histone deacetylase
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
AP1699A (en) 2001-03-21 2006-12-26 Warner Lambert Co New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
DE60238674D1 (de) 2001-04-19 2011-02-03 Mitsubishi Tanabe Pharma Corp Polymorphe formen von n-(2,3-dimethyl-5,6,7,8-tetrahydrofuro(2,3-b)quinolin-4-yl)-2-(2-oxopyrrolidin-1 -yl)acetamid
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
GB0111191D0 (en) 2001-05-08 2001-06-27 Merck Sharp & Dohme Therapeutic agents
AU2002305523A1 (en) 2001-05-09 2002-11-18 President And Fellows Of Harvard College Dioxanes and uses thereof
MXPA03010961A (es) 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
CA2450271A1 (en) 2001-06-12 2002-12-19 Sk Corporation Novel phenylalkyl diamine and amide analogs
WO2002102313A2 (en) 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
GB0117060D0 (en) 2001-07-12 2001-09-05 Merck Sharp & Dohme Therapeutic agents
US20040235884A1 (en) 2001-08-06 2004-11-25 Ken Takashina Preventives/remedies for cholinergic neuropathy
EP1285922A1 (en) 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
WO2003024448A2 (en) 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
EP1295885A1 (en) 2001-09-21 2003-03-26 Sanofi-Synthelabo Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
EP1295884A1 (en) 2001-09-21 2003-03-26 Sanofi-Synthelabo 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives
RU2004112787A (ru) 2001-09-26 2005-10-10 Байер Фармасьютикалс Корпорейшн (US) Производные 1,6-нафтиридина как противодиабетические средства
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003028650A2 (en) 2001-10-02 2003-04-10 Acadia Pharmaceuticals, Inc. Benzimidazolidinone derivatives as muscarinic agents
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
EP1443922A1 (en) 2001-10-25 2004-08-11 Schering Corporation Mch antagonists for the treatment of obesity
CN1582277A (zh) 2001-11-01 2005-02-16 詹森药业有限公司 用作糖原合酶激酶3β抑制剂的酰胺衍生物
MXPA04004178A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
CA2467269C (en) 2001-11-14 2011-04-05 Weiqin Jiang Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
AU2002365892A1 (en) 2001-11-30 2003-06-17 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
WO2003053975A1 (en) 2001-12-13 2003-07-03 Daiichi Suntory Pharma Co., Ltd. Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
ES2295441T3 (es) 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
EP1458708B1 (en) 2001-12-18 2007-09-26 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
EP1458385A4 (en) 2001-12-19 2005-12-21 Merck & Co Inc METABOTROPIC GLUTAMATE RECEPTOR 5-HETEROARYL-SUBSTITUTED IMIDAZOLE MODULATORS
EP1458710A4 (en) 2001-12-21 2005-04-20 Merck & Co Inc Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5
DE10163991A1 (de) 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
CA2366325A1 (en) 2001-12-27 2003-06-27 Todd Howley Method of forming turbine blade root
ATE405289T1 (de) 2001-12-27 2008-09-15 Taisho Pharmaceutical Co Ltd 6-fluorobicyclo 3.1.0 hexan-derivate
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
NZ533566A (en) 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
KR100974901B1 (ko) 2001-12-28 2010-08-10 아카디아 파마슈티칼스 인코포레이티드 모노아민 수용체 조정자로서의 스피로아자사이클릭 화합물
US6495700B1 (en) 2002-01-09 2002-12-17 Axonyx, Inc. Process for producing phenserine and its analog
EP1468684A4 (en) 2002-01-22 2008-02-27 Eisai R&D Man Co Ltd SIGMA RECEPTOR BINDING MOLECULE WITH INDANO DERIVATIVE
US7378428B2 (en) 2002-01-31 2008-05-27 Ono Pharmaceutical Co., Ltd. Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient
PL372756A1 (en) 2002-02-11 2005-08-08 Pfizer Inc. Nicotinamide derivatives useful as pde4 inhibitors
CA2477117A1 (en) 2002-02-22 2003-08-28 Teijin Limited Pyrrolopyrimidine derivative
ATE486600T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
AU2003218737B2 (en) 2002-03-13 2008-04-10 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
ES2306880T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonilamino como inhibidores novedosos de la histona desacetilasa.
ATE395343T1 (de) 2002-03-13 2008-05-15 Janssen Pharmaceutica Nv Sulfonylderivate als histone-deacetylase- inhibitoren
EA007270B1 (ru) 2002-03-13 2006-08-25 Янссен Фармацевтика Н.В. Пиперазинил-, пиперидинил- и морфолинилпроизводные как новые ингибиторы гистондеацетилазы
ES2284739T3 (es) 2002-03-20 2007-11-16 Societe Des Produits Nestle S.A. Extracto de cacao con bajo contenido en grasa.
US7514107B2 (en) 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
BR0308908A (pt) 2002-04-03 2005-01-04 Topotarget Uk Ltd Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0212048D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
JP4916662B2 (ja) 2002-06-19 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ホスホジエステラーゼ阻害剤として有用な置換２，４−ジヒドロ−ピロロ（３，４−ｂ）−キノリン−９−オン誘導体
CA2492907A1 (en) 2002-07-19 2004-01-29 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
EP1400244A1 (en) 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
EP1572099A4 (en) 2002-10-04 2007-01-03 Univ California SCREENING AND THERAPEUTIC METHODS RELATED TO THE NEUROGENESIS
EP1556355A1 (en) 2002-10-21 2005-07-27 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
DK1583541T3 (da) 2002-11-20 2011-04-11 Neuronova Ab Forbindelser og fremgangsmåder til at øge neurogenese
ES2209650B2 (es) 2002-12-09 2006-11-01 Laboratorios Del Dr. Esteve, S.A. Mamiferos no humanos mutantes deficientes en receptores sigma y sus aplicaciones.
WO2004053071A2 (en) 2002-12-09 2004-06-24 Judith Kelleher-Andersson Method for discovering neurogenic agents
CA2512765A1 (en) * 2003-01-08 2004-07-29 Mitsubishi Pharma Corporation Therapeutic agent for schizophrenia
TW200418806A (en) 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
MXPA05008186A (es) 2003-01-31 2005-10-05 Astrazeneca Ab Derivados de quinoxalina saturados y su uso como ligandos receptores de glutamato metabotropico.
US6969716B2 (en) 2003-02-07 2005-11-29 Merck Sharp & Dohme Ltd. 5-phenyl[1,2,4]triazines as ligands for GABA-A α2/α3 receptors for treating anxiety or depression
AU2004212421B2 (en) 2003-02-07 2009-08-20 Vertex Pharmaceuticals Incorporated Heteroaryl substituted pyrolls useful as inhibitors of protein kinases
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
JP2006521399A (ja) 2003-03-28 2006-09-21 アカディア ファーマシューティカルズ，インコーポレーテッド 疼痛管理用ムスカリンｍ１受容体アゴニスト
ATE365554T1 (de) 2003-04-04 2007-07-15 Dynogen Pharmaceuticals Inc Methode zur behandlung von erkrankungen der unteren harnwege
JP2006523710A (ja) 2003-04-16 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４インヒビター
US20040254152A1 (en) 2003-04-17 2004-12-16 Monje Michelle L. Prevention of deficits in neurogenesis with anti-inflammatory agents
GB0311859D0 (en) 2003-05-22 2003-06-25 Merck Sharp & Dohme Therapeutic agents
US7763588B2 (en) 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
US7842835B2 (en) 2003-07-07 2010-11-30 Georgetown University Histone deacetylase inhibitors and methods of use thereof
KR100764330B1 (ko) 2003-07-25 2007-10-05 에프. 호프만-라 로슈 아게 급성 및/또는 만성 신경학적 장애의 치료를 위한ｍＧｌｕＲ2 길항제 및 ＡＣｈＥ 억제제의 조합물
US20050031538A1 (en) 2003-08-05 2005-02-10 Steindler Dennis A. Neural cell assay
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
EP1670455A4 (en) 2003-10-10 2008-10-15 Mars Inc TREATMENT OF DISEASES WITH ERBB2-KINASE OVEREXPRESSION
SI1541197T1 (sl) * 2003-12-02 2009-08-31 Pharmaneuroboost N V Uporaba pipamperona in sndri, snri ali ssri za zdravljenje razpoloĺ˝enjskih ali tesnobnih motenj
WO2005065681A1 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
WO2005066151A2 (en) 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2550735A1 (en) 2003-12-22 2005-07-14 Acadia Pharmaceuticals Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
EP1718280A4 (en) 2004-01-30 2010-08-18 Mars Inc METHOD AND COMPOSITIONS FOR CANCER TREATMENT
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US20070015138A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
CN101378752A (zh) * 2006-02-07 2009-03-04 田边三菱制药株式会社 4-酰氨基吡啶衍生物介导的神经发生

Also Published As

Publication number Publication date
WO2008030651A1 (en) 2008-03-13
BRPI0716604A2 (pt) 2013-04-09
JP2010502722A (ja) 2010-01-28
EP2068872A1 (en) 2009-06-17
AU2007292848A1 (en) 2008-03-13
US20080064671A1 (en) 2008-03-13
US7998971B2 (en) 2011-08-16
MX2009002496A (es) 2009-07-10
KR20090064418A (ko) 2009-06-18

Similar Documents

Publication Publication Date Title
US7998971B2 (en) Combinations containing a 4-acylaminopyridine derivative
US7678808B2 (en) 5 HT receptor mediated neurogenesis
US7858611B2 (en) Neurogenesis by modulating angiotensin
US7985756B2 (en) Modulation of neurogenesis by PDE inhibition
US20080103165A1 (en) Ppar mediated modulation of neurogenesis
US20080108574A1 (en) Melanocortin receptor mediated modulation of neurogenesis
US20070244143A1 (en) Modulation of neurogenesis by nootropic agents
US20080188457A1 (en) Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
US20080103105A1 (en) HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
EP2377531A2 (en) Neurogenesis by modulating angiotensin
US20080167363A1 (en) Modulation of Neurogenesis By Melatoninergic Agents
US20100216805A1 (en) Modulation of neurogenesis using d-cycloserine combinations
US20080171750A1 (en) Modulation Of Neurogenesis With Use of Modafinil
WO2011063115A1 (en) Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130621